PPD, Inc. PPD
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 47.32
- Prev close
- 47.28
- Mkt cap
- 16.61B
- Vol
- 1.87M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 47.24
- High
- 47.40
- Forward P/E
- 25.56
- Beta
- 0.00
- Short ratio
- 10.87
- Inst. own
- 79.44%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 27, 2021
- 50-d avg
- 47.14
- 200-d avg
- 45.20
- 1y target
- 47.14
Key statistics
- Market cap
- 16.61B
- Enterprise value
- 19.96B
- Trailing P/E
- 47.04
- Forward P/E
- 25.56
- PEG ratio
- 1.65
- Price / sales
- 2.83
- Price / book
- 0.00
- EPS (TTM)
- 1.01
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 6.19%
- Revenue (TTM)
- 5.88B
- Revenue growth
- 26.50%
- Free cash flow
- 469.11M
- Total cash
- 1.17B
- Total debt
- 4.48B
- Return on equity
- 0.00%
- Shares outstanding
- 351.40M
- Short % of float
- 9.57%
- 50-day average
- 47.14
- 200-day average
- 45.20
Analyst view
Consensus: hold
- Target (low)
- 45.00
- Target (mean)
- 47.14
- Target (high)
- 48.00
Next earnings
Oct 27, 2021
Expected Oct 27, 2021. Consensus EPS estimate 0.45.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 27, 2021 | Sep 1, 2021 | 0.37 | — | — | — |
| Jul 28, 2021 | Jun 1, 2021 | 0.34 | — | — | — |
| Apr 27, 2021 | Mar 1, 2021 | 0.31 | — | — | — |
| Feb 23, 2021 | Dec 1, 2020 | 0.35 | — | — | — |
| Oct 27, 2020 | Sep 1, 2020 | 0.32 | — | — | — |
| Aug 4, 2020 | Jun 1, 2020 | 0.22 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 28, 2021 | JP Morgan | down | Overweight | Neutral |
| Apr 20, 2021 | Jefferies | down | Buy | Hold |
| Apr 19, 2021 | Citigroup | down | Buy | Neutral |
| Apr 19, 2021 | Credit Suisse | down | Outperform | Neutral |
| Apr 16, 2021 | Truist Securities | down | Buy | Hold |
| Apr 16, 2021 | Deutsche Bank | down | Buy | Hold |
About PPD, Inc.
PPD, Inc., together with its subsidiaries, provides drug development services to the biopharmaceutical industry worldwide. The company operates through two segments, Clinical Development Services and Laboratory Services. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri-and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company has a collaboration with Science 37 to design, build, test, implement, and execute digital trials using Science 37's DCT SaaS-based technology platform. PPD, Inc. was founded in 1985 and is headquartered in Wilmington, North Carolina. As of December 8, 2021, PPD, Inc. operates as a subsidiary of Thermo Fisher Scientific Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- ppd.com
News
- Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
- Thermo Fisher Scientific's PPD Clinical Research Business Collaborates with HealthVerity to Expand Real-World Data Capabilities
- Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
- Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Thermo Fisher Scientific Launches PPD CorEvitas Alzheimer's Disease Registry to Advance Real-World Evidence in Neurodegenerative Care
- Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
- Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
- Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
- Reunion Neuroscience Announces Last Patient Dosed in RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
Your note
Sign in to keep a note on PPD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONOVAN GLEN | Officer | Sale | Mar 2, 2021 | 3,000 |
| GARROW RONALD E | Officer | Sale | Mar 1, 2021 | 0 |
| HARTMAN BRAINARD JUDD | General Counsel | Sale | Sep 28, 2020 | 64,166 |
| HILADO MARIA TERESA | Director | Stock Award(Grant) | Apr 22, 2021 | 39,363 |
| HILL COLIN | Director | Stock Award(Grant) | Apr 22, 2021 | 16,330 |
| JAMES JULIA | General Counsel | Stock Gift | May 12, 2021 | 21,470 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| H&F Corporate Investors VII, Ltd. | 21.95% | 77,118,535 | 3.61B | Sep 29, 2021 |
| Carlyle Group Inc. | 15.86% | 55,722,733 | 2.61B | Sep 29, 2021 |
| H&F Corporate Investors VIII, Ltd | 15.86% | 55,722,731 | 2.61B | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 3.41% | 11,982,265 | 560.65M | Sep 29, 2021 |
| Pentwater Capital Management Lp | 3.03% | 10,640,000 | 497.85M | Sep 29, 2021 |
| Blackrock Inc. | 2.49% | 8,733,668 | 408.65M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.13% | 3,976,021 | 186.04M | Sep 29, 2021 |
| Merger Fund, The | 0.93% | 3,268,854 | 152.95M | Sep 29, 2021 |
| Vanguard Mid-Cap Index Fund | 0.90% | 3,171,405 | 148.39M | Sep 29, 2021 |
| Vanguard Extended Market Index Fund | 0.45% | 1,571,275 | 73.52M | Sep 29, 2021 |
| Arbitrage Fund | 0.41% | 1,438,137 | 66.60M | Aug 30, 2021 |
| Vanguard Growth Index Fund | 0.32% | 1,109,217 | 51.90M | Sep 29, 2021 |